Canada to donate 17.7 mn AstraZeneca Covid-19 vaccine to other countries

Canada announced its decision to donate 17.7 million doses of the AstraZeneca coronavirus vaccine to low- and middle-income countries

AstraZeneca, pharma, coronavirus, vaccine
IANS Ottawa
2 min read Last Updated : Jul 13 2021 | 10:59 AM IST

Canada announced its decision to donate 17.7 million doses of the AstraZeneca coronavirus vaccine to low- and middle-income countries.

While addressing a press conference on Monday, Procurement Minister Anita Anand said that the vaccine doses are a part of the Canadian government's advance purchase agreement with the company and would be distributed through COVAX, reports Xinhua news agency.

COVAX is a global vaccine-sharing initiative jointly co-ordinated by the World Health Organization, the Coalition for Epidemic Preparedness Innovations and Gavi, the Vaccine Alliance.

"This donation is a result of our proactive approach to securing hundreds of millions of Covid-19 vaccines in our initial contracts. With close to 55 million vaccines in Canada, and with the demands of the provinces and territories for this vaccine being met, we are now in a position to donate these excess doses," Anand said.

The government also announced it's partnering with Unicef on a donation-matching fundraising campaign to encourage Canadians to donate vaccine doses by contributing C$10.

All donations by Canadians will be matched by the federal government, up to a maximum of C$10 million).

The campaign runs until September 6.

Anand said that if the Unicef campaign is maxed out, it will provide enough money to vaccinate 4 million people in countries where inoculation campaigns are struggling to meet demand.

She said that the AstraZeneca doses are coming from the advance purchase agreement the government struck with the company and that these doses, which will be manufactured in the United States, will start being delivered to COVAX in the coming weeks.

The Public Health Agency of Canada and the National Advisory Committee on Immunization have "recommended" mRNA vaccines such as Moderna or Pfizer over AstraZeneca's product.

The recommendation was made in the wake of evidence suggesting that, in rare cases, the AstraZeneca vaccine could cause potentially fatal blood clots in some people.

--IANS

ksk/

 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineAstraZenecaCanada

First Published: Jul 13 2021 | 10:59 AM IST

Next Story